Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic Syndromes 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

fludarabine phosphate 16Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 10Tacrolimus 9Busulfan 9Whole-Body Irradiation 8Mycophenolic Acid 8fludarabine 6Methotrexate 6Cyclosporine 6Radiotherapy 5ruxolitinib 4Biopsy 4Antilymphocyte Serum 4Specimen Handling 3Decitabine 3peginterferon alfa-2a 2givinostat hydrochloride 2givinostat 2bomedemstat 2Stem Cell Transplantation 2Prednisone 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Melphalan 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Cytarabine 2Aspirin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thrombocythemia, Essential × piperine × Clear all
NCT06063486 2026-03-27

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

University of Southern California

Phase 2 Recruiting
30 enrolled
Myeloid

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡